Abstract
Bone and soft tissue sarcomas (BSTSs) represent a heterogeneous group of rare malignant tumors with a wide spectrum in terms of histologic type, location, and outcome. Surgery, chemotherapy, and radiotherapy, alone or in combination, have been employed for the treatment of BSTSs. Major role of radiotherapy has been considered to be adjuvant of surgery. Radiotherapy alone was indicated for patients with locally advanced, inoperable, recurrent, or metastatic disease. Of the 1,462 patients treated in the clinical trials between June 1994 and February 2003, one hundred and thirty nine had bone or soft tissue sarcomas not suitable for surgical resection. Carbon ion radiotherapy of the patients with BSTS was initiated under our phase I/II dose escalation protocol and a total of 59 patients were enrolled in the trial during the period from 1996 through 2000. A phase II study was followed in April 2000, and 80 patients were enrolled in the study until February 2003. BSTSs were one of the most radio-resistant tumors, however, two years local control rates in 2 studies were 77% and 90%. Four years survival rate was 47% in the phase I/II study. Carbon ion radiotherapy seems to be a safe and effective modality in the management
More>>
Kamada, Tadashi;
Tsuji, Hiroshi;
Yanagi, Tsuyoshi;
Ishikawa, Hitoshi;
Wakatsuki, Masaru;
Imai, Reiko;
[1]
Tatezaki, Shinichiro
[2]
- National Inst. of Radiological Sciences, Chiba (Japan). Research Center Hospital for Charged Particle Therapy
- Chiba Cancer Center (Japan)
Citation Formats
Kamada, Tadashi, Tsuji, Hiroshi, Yanagi, Tsuyoshi, Ishikawa, Hitoshi, Wakatsuki, Masaru, Imai, Reiko, and Tatezaki, Shinichiro.
Bone and soft tissue sarcomas.
Japan: N. p.,
2004.
Web.
Kamada, Tadashi, Tsuji, Hiroshi, Yanagi, Tsuyoshi, Ishikawa, Hitoshi, Wakatsuki, Masaru, Imai, Reiko, & Tatezaki, Shinichiro.
Bone and soft tissue sarcomas.
Japan.
Kamada, Tadashi, Tsuji, Hiroshi, Yanagi, Tsuyoshi, Ishikawa, Hitoshi, Wakatsuki, Masaru, Imai, Reiko, and Tatezaki, Shinichiro.
2004.
"Bone and soft tissue sarcomas."
Japan.
@misc{etde_20650899,
title = {Bone and soft tissue sarcomas}
author = {Kamada, Tadashi, Tsuji, Hiroshi, Yanagi, Tsuyoshi, Ishikawa, Hitoshi, Wakatsuki, Masaru, Imai, Reiko, and Tatezaki, Shinichiro}
abstractNote = {Bone and soft tissue sarcomas (BSTSs) represent a heterogeneous group of rare malignant tumors with a wide spectrum in terms of histologic type, location, and outcome. Surgery, chemotherapy, and radiotherapy, alone or in combination, have been employed for the treatment of BSTSs. Major role of radiotherapy has been considered to be adjuvant of surgery. Radiotherapy alone was indicated for patients with locally advanced, inoperable, recurrent, or metastatic disease. Of the 1,462 patients treated in the clinical trials between June 1994 and February 2003, one hundred and thirty nine had bone or soft tissue sarcomas not suitable for surgical resection. Carbon ion radiotherapy of the patients with BSTS was initiated under our phase I/II dose escalation protocol and a total of 59 patients were enrolled in the trial during the period from 1996 through 2000. A phase II study was followed in April 2000, and 80 patients were enrolled in the study until February 2003. BSTSs were one of the most radio-resistant tumors, however, two years local control rates in 2 studies were 77% and 90%. Four years survival rate was 47% in the phase I/II study. Carbon ion radiotherapy seems to be a safe and effective modality in the management of BSTSs not eligible for surgical resection, providing good local control and offering a survival advantage without unacceptable morbidity. (author)}
place = {Japan}
year = {2004}
month = {Jul}
}
title = {Bone and soft tissue sarcomas}
author = {Kamada, Tadashi, Tsuji, Hiroshi, Yanagi, Tsuyoshi, Ishikawa, Hitoshi, Wakatsuki, Masaru, Imai, Reiko, and Tatezaki, Shinichiro}
abstractNote = {Bone and soft tissue sarcomas (BSTSs) represent a heterogeneous group of rare malignant tumors with a wide spectrum in terms of histologic type, location, and outcome. Surgery, chemotherapy, and radiotherapy, alone or in combination, have been employed for the treatment of BSTSs. Major role of radiotherapy has been considered to be adjuvant of surgery. Radiotherapy alone was indicated for patients with locally advanced, inoperable, recurrent, or metastatic disease. Of the 1,462 patients treated in the clinical trials between June 1994 and February 2003, one hundred and thirty nine had bone or soft tissue sarcomas not suitable for surgical resection. Carbon ion radiotherapy of the patients with BSTS was initiated under our phase I/II dose escalation protocol and a total of 59 patients were enrolled in the trial during the period from 1996 through 2000. A phase II study was followed in April 2000, and 80 patients were enrolled in the study until February 2003. BSTSs were one of the most radio-resistant tumors, however, two years local control rates in 2 studies were 77% and 90%. Four years survival rate was 47% in the phase I/II study. Carbon ion radiotherapy seems to be a safe and effective modality in the management of BSTSs not eligible for surgical resection, providing good local control and offering a survival advantage without unacceptable morbidity. (author)}
place = {Japan}
year = {2004}
month = {Jul}
}